Tony Leuang
Payments from drug & device makers
Across 629 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sanofi$2K
- LEO Pharma Inc.$1K
- UCB, Inc.$1K
- Pfizer$933
- Lilly USA, LLC$927
- plus $4K from 17 others
What the payments were for
- Consulting fees$4063%
- Food & beverage$11,83192%
- Education$5714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 146 | $2,577 |
| Sanofi | 50 | $1,964 |
| LEO Pharma Inc. | 63 | $1,234 |
| UCB, Inc. | 57 | $1,204 |
| Pfizer | 53 | $933 |
| Lilly USA, LLC | 57 | $927 |
| Johnson & Johnson | 46 | $857 |
| Regeneron Healthcare Solutions, Inc. | 34 | $706 |
| Amgen | 37 | $641 |
| Novartis | 14 | $334 |
| Galderma Laboratories, L.p. | 19 | $299 |
| Arcutis Biotherapeutics, Inc. | 19 | $278 |
| Sun Pharmaceutical Industries Inc. | 6 | $262 |
| Incyte Corporation | 10 | $246 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Botanix SB Inc | 2 | $49 |
| Biofrontera Inc. | 2 | $38 |
| Strata Skin Sciences, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Organon | 2 | $22 |
| Verrica Pharmaceuticals Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
How this compares
$12,809 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 28 | $556,929 |
| Dupixent PenDupilumab | 94 | $360,447 |
| Humira(Cf) PenAdalimumab | 15 | $189,527 |
| Taltz AutoinjectorIxekizumab | 14 | $120,404 |
| Fluocinonide | 98 | $3,065 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 43 | $2,864 |
| Fluorouracil | 33 | $2,507 |
| Clobetasol Propionate | 79 | $2,465 |
| Tacrolimus | 19 | $1,624 |
| Clindamycin Phosphate | 64 | $1,561 |
| Ketoconazole | 113 | $1,429 |
| Tretinoin | 19 | $1,308 |
| Econazole Nitrate | 19 | $832 |
| Cephalexin | 95 | $714 |
| Ciclopirox | 27 | $713 |
Paid to pharmacies, not to this prescriber.
Other medical in Indio
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.